Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

ClinicalTrials.gov ID: NCT00976937

Public ClinicalTrials.gov record NCT00976937. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin

Study identification

NCT ID
NCT00976937
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
319 participants

Conditions and interventions

Interventions

  • Lixisenatide (AVE0010) Drug
  • Lixisenatide Placebo Drug
  • Metformin Drug
  • Pen auto-injector Device
  • Sitagliptin Drug
  • Sitagliptin Placebo Drug

Drug · Device

Eligibility (public fields only)

Age range
18 Years to 49 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2009
Primary completion
Feb 28, 2011
Completion
Feb 28, 2011
Last update posted
Oct 10, 2016

2009 – 2011

United States locations

U.S. sites
21
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
Sanofi-Aventis Investigational Site Number 840019 Montgomery Alabama 36109
Sanofi-Aventis Investigational Site Number 840003 Muscle Shoals Alabama 35661
Sanofi-Aventis Investigational Site Number 840022 Mesa Arizona 85206
Sanofi-Aventis Investigational Site Number 840011 Anaheim California 92801
Sanofi-Aventis Investigational Site Number 840014 Paramount California 90723
Sanofi-Aventis Investigational Site Number 840027 Redlands California 92374
Sanofi-Aventis Investigational Site Number 840021 Augusta Georgia 30909
Sanofi-Aventis Investigational Site Number 840007 Roswell Georgia 30076
Sanofi-Aventis Investigational Site Number 840016 Chicago Illinois 60610
Sanofi-Aventis Investigational Site Number 840018 Chicago Illinois 60616
Sanofi-Aventis Investigational Site Number 840001 Evansville Indiana 47714
Sanofi-Aventis Investigational Site Number 840002 Baton Rouge Louisiana 70808
Sanofi-Aventis Investigational Site Number 840031 Clarkston Michigan 48346
Sanofi-Aventis Investigational Site Number 840020 Florissant Missouri 63031
Sanofi-Aventis Investigational Site Number 840006 Butte Montana 59701
Sanofi-Aventis Investigational Site Number 840026 Perrysburg Ohio 43551
Sanofi-Aventis Investigational Site Number 840004 Medford Oregon 97504
Sanofi-Aventis Investigational Site Number 840025 Altoona Pennsylvania 16602
Sanofi-Aventis Investigational Site Number 840009 Brentwood Tennessee 37207
Sanofi-Aventis Investigational Site Number 840008 Dallas Texas 75230
Sanofi-Aventis Investigational Site Number 840010 San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00976937, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 10, 2016 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00976937 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →